A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

NCT06075043 | Not Yet Recruiting Phase 2

• 1 other identifier: AND017-CRA-202
• Study Type: interventional
• Target: 36
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to determine the safety and efficacy of various doses of AND017 after 6 weeks of treatment in subjects with anemia of cancer who are not receiving chemotherapy.

Conditions

Cancer-Related Anemia

Outcome Measures

Primary Outcomes (1)

• Percentage of responding patients

  Responding patient is defined as those with a maximum elevated hemoglobin level greater than 10% of baseline from baseline to five weeks after dosing.

  From Baseline to Week 6 or End of Treatment visit

Secondary Outcomes (5)

• Transfusion treatment rate

  From Baseline to Week 6 or End of Treatment visit

• Maximum change in hemoglobin from baseline to 5 weeks post-dose

  From Baseline to Week 6 or End of Treatment visit

• Percentage of visits in which subjects maintained a hemoglobin elevation between >10% and 12.0 g/dL above baseline after reaching 10% of baseline

  From Baseline to Week 6 or at End of Treatment visit

• Percentage of patients who achieve a greater than 10% increase in hemoglobin over baseline during treatment

  From Baseline to Week 6 or at End of Treatment visit

• Percentage of subjects requiring blood transfusions during the trial

  From Baseline to Week 6 or at End of Treatment visit

Study Arms (3)

AND017 Dose A three times weekly

EXPERIMENTAL

Drug: AND017

AND017 Dose B three times weekly

EXPERIMENTAL

Drug: AND017

AND017 Dose C three times weekly

EXPERIMENTAL

Drug: AND017

Interventions

AND017 DRUG

Oral administration of AND017 capsules three times per week

AND017 Dose A three times weekly; AND017 Dose B three times weekly; AND017 Dose C three times weekly

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Non-myeloid malignancy diagnosed by cytology/histology.
• ECOG score 0-2 and expected survival of 6 months or more.
• The mean value of hemoglobin at screening test and one follow-up test (more than one week between tests) was \<10.0 g/dL, with a difference of ≤1.0 g/dL between the two tests.
• Adequate hepatic and renal function.
• Total bilirubin \< 1.5 x upper limit of normal (ULN).
• Subjects with Gilbert's syndrome (unconjugated hyperbilirubinemia) have a total bilirubin \< 3 x ULN.
• Aspartate aminotransferase (AST)
• Alanine aminotransferase (ALT) \<2.5 x ULN
• eGFR \>60 mL/min/1.73

You may not qualify if:

• Received chemotherapy, radiotherapy, and other, e.g., immunosuppressive, targeted drug therapy that has a suppressive effect on the bone marrow within 1 month prior to randomization or planned during the trial.
• A medical history of significant liver disease or active liver disease.
• A previous history of pure red blood cell remittance
• A combination of hereditary anemia, iron-granulocytic anemia, acute blood loss, active bleeding (three consecutive positive fecal occult bloods or clinical judgment of the investigator), hemolysis and other conditions that can cause anemia such as iron, folic acid or vitamin B12 deficiency
• Active infection or inflammatory disease requiring systemic anti-infective therapy within 1 week prior to the first dose, including concurrent autoimmune diseases with inflammatory symptoms (e.g., generalized erythema, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis, dry syndrome, celiac disease, etc.)
• Concurrent retinal neovascularization requiring treatment (diabetic proliferative retinopathy, age-related exudative macular degeneration, retinal vein occlusion, macular edema, etc.).
• clinically significant bleeding (including the need for blood transfusion or a drop in hemoglobin ≥ 2 g/dL) within 4 weeks prior to the first dose, or a bleeding constitutional or bleeding risk that has not been medically or surgically corrected
• uncontrolled hypertension (more than one-third of identifiable diastolic blood pressure values \> 90 mmHg and/or systolic blood pressure ≥ 160 mmHg at 16 weeks prior to and including screening testing)
• concurrent congestive heart failure (New York Heart Association \[NYHA\] class III or higher)
• clinically significant ECG abnormalities at screening assessment.
• Have been treated with any hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in the 8 weeks prior to randomization
• have received treatment with an erythropoietic agent, androgenic anabolic steroid, testosterone enanthate or methandrostenolone within 6 weeks prior to screening assessment.
• a history of significant medical or major surgical procedure within 3 months prior to the screening assessment or elective surgery planned during the conduct of the study.

Sponsors & Collaborators

• Kind Pharmaceuticals LLC: lead

Study Officials

• Yusha Zhu, MD, PhD

  Kind Pharmaceuticals LLC

  STUDY DIRECTOR

Central Study Contacts

Yusha Zhu, MD, PhD

CONTACT

6467252552; yushazhu@kindpharmaceutical.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 22, 2023
• First Posted: October 10, 2023
• Study Start (Estimated): December 1, 2027
• Primary Completion (Estimated): May 1, 2028
• Study Completion (Estimated): August 1, 2028
• Last Updated: February 27, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share